Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–1 of 1 matching trial from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Blasts 30 Percent or Less of Bone Marrow Nucleated Cells Clear all

Completed Phase 1 Interventional Results available

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT03358719

View directory record Official record

Conditions: Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Refractory Anemia
Interventions: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis, Nivolumab, Poly ICLC; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Feb 26, 2026 · Synced May 21, 2026, 6:19 PM EDT